NYSE:PEN - Penumbra Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Penumbra Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $155.12 -6.21 (-3.85 %) (As of 04/1/2020 12:40 PM ET) Add Compare Today's Range$155.02Now: $155.13▼$161.3350-Day Range$124.34MA: $169.73▼$193.7652-Week Range$121.80Now: $155.13▼$194.93Volume107,460 shsAverage Volume437,180 shsMarket Capitalization$5.44 billionP/E Ratio114.91Dividend YieldN/ABeta0.75 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.Read More Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:PEN Previous Symbol CUSIPN/A CIK1321732 Webhttp://www.penumbrainc.com/ Phone510-748-3200Debt Debt-to-Equity Ratio0.15 Current Ratio5.09 Quick Ratio3.41Price-To-Earnings Trailing P/E Ratio114.91 Forward P/E Ratio128.20 P/E GrowthN/A Sales & Book Value Annual Sales$547.41 million Price / Sales9.93 Cash Flow$1.19 per share Price / Cash Flow130.41 Book Value$13.91 per share Price / Book11.15Profitability EPS (Most Recent Fiscal Year)$0.98 Net Income$48.46 million Net Margins8.85% Return on Equity7.72% Return on Assets5.85%Miscellaneous Employees2,700 Outstanding Shares35,050,000Market Cap$5.44 billion Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive PEN News and Ratings via Email Sign-up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter. PEN Rates by TradingView Penumbra (NYSE:PEN) Frequently Asked Questions How has Penumbra's stock been impacted by COVID-19 (Coronavirus)? Penumbra's stock was trading at $176.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PEN stock has decreased by 10.2% and is now trading at $158.89. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Penumbra? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Penumbra. When is Penumbra's next earnings date? Penumbra is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Penumbra. How were Penumbra's earnings last quarter? Penumbra Inc (NYSE:PEN) released its earnings results on Tuesday, February, 25th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.04. The firm had revenue of $145.26 million for the quarter, compared to analysts' expectations of $141.64 million. Penumbra had a return on equity of 7.72% and a net margin of 8.85%. View Penumbra's earnings history. What guidance has Penumbra issued on next quarter's earnings? Penumbra issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $635-645 million, compared to the consensus revenue estimate of $651.96 million. What price target have analysts set for PEN? 8 brokers have issued 12 month price objectives for Penumbra's shares. Their forecasts range from $180.00 to $200.00. On average, they anticipate Penumbra's share price to reach $190.67 in the next year. This suggests a possible upside of 20.0% from the stock's current price. View analysts' price targets for Penumbra. Has Penumbra been receiving favorable news coverage? News coverage about PEN stock has been trending very negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Penumbra earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutPenumbra. Are investors shorting Penumbra? Penumbra saw a decrease in short interest during the month of March. As of March 13th, there was short interest totaling 3,402,700 shares, a decrease of 13.2% from the February 27th total of 3,920,000 shares. Based on an average trading volume of 312,800 shares, the short-interest ratio is presently 10.9 days. Approximately 10.4% of the shares of the stock are short sold. View Penumbra's Current Options Chain. Who are some of Penumbra's key competitors? Some companies that are related to Penumbra include ResMed (RMD), FRESENIUS SE &/S (FSNUY), Teleflex (TFX), Insulet (PODD), Hill-Rom (HRC), ABIOMED (ABMD), Novocure (NVCR), Haemonetics (HAE), Globus Medical (GMED), ICU Medical (ICUI), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), Nevro (NVRO), NuVasive (NUVA) and Irhythm Technologies (IRTC). What other stocks do shareholders of Penumbra own? Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), Splunk (SPLK), AbbVie (ABBV), salesforce.com (CRM), Intuitive Surgical (ISRG), Adobe (ADBE), DexCom (DXCM) and Paypal (PYPL). Who are Penumbra's key executives? Penumbra's management team includes the following people: Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 57)Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 57)Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 41)Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 58)Mr. Daniel Donen Davis, Chief Commercial Officer (Age 41) What is Penumbra's stock symbol? Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN." How do I buy shares of Penumbra? Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Penumbra's stock price today? One share of PEN stock can currently be purchased for approximately $158.89. How big of a company is Penumbra? Penumbra has a market capitalization of $5.57 billion and generates $547.41 million in revenue each year. The company earns $48.46 million in net income (profit) each year or $0.98 on an earnings per share basis. Penumbra employs 2,700 workers across the globe. View additional information about Penumbra. What is Penumbra's official website? The official website for Penumbra is http://www.penumbrainc.com/. How can I contact Penumbra? Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected] MarketBeat Community Rating for Penumbra (NYSE PEN)Community Ranking: 3.8 out of 5 ( )Outperform Votes: 689 (Vote Outperform)Underperform Votes: 226 (Vote Underperform)Total Votes: 915MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe PEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/1/2020 by MarketBeat.com StaffFeatured Article: What is the Shanghai Stock Exchange Composite Index?
